Medical Science Liaison Society Establishes Global Advisory Committee

Team Boasts Breadth, Depth with 17 Members from Around the World

Highland Beach, FL, May 16, 2015 –(– The Medical Science Liaison Society (MSL Society) — the world’s first and only non-profit organization dedicated to the advancement of the medical science liaison (MSL) role in the pharmaceutical and other healthcare industries — is proud to announce the launch of its inaugural global Advisory Committee.

The MSL Advisory Committee will provide critical support for MSL Society members, assessing needs and designating priorities for initiatives such as educational programs and networking events sponsored by the society in its unwavering advocacy for professional growth and development of MSLs around the world. The Advisory Committee will play a vital role in MSL Society outreach, and in upcoming society newsletters, committee members plan to offer insights and best practices for its constituents.

From six countries spanning the globe, the committee members hail from a range of backgrounds — from those currently serving as medical affairs executives and MSLs, to others from support industries and partner organizations such as healthcare consultancy and leader in KOL profiling, Thought Leader Select, and digital marketing agency, Global Prairie. Set to chair the society during its first year is Dr. Alexander Tolmachev, Senior Manager for Medical and Regulatory Projects at Russian-based Takeda Pharmaceuticals.

“We’re both excited and honored to have such an extraordinary group of individuals join forces to serve our organization,” said Dr. Samuel Dyer, Chairman of the Board for the MSL Society. “The collective talent and depth of expertise of this team is truly remarkable, and I look forward to working with them to continue driving the upward momentum we’ve worked so hard to create on behalf of our members.”

The following will comprise the MSL Society’s global advisory committee throughout its first year:

• Alexander Tolmachev, Chair
Senior Manager, Medical and Regulatory Projects — Takeda (Russia)

• Jamshed Ahmed
Director, Medical Affairs — Sanofi (Australia)

• Goce Bogeski
Medical Science Liaison — Biogen Idec (Australia)

• Hudson Garrett, Ph.D., MSN, MPH, FNP, CSRN, VA-BC™, DON-CLTC™, C-NAC™, PLNC
Vice President Clinical Affairs — PDI Inc. and Nice-Pak (USA)

• Jasmina Jankicevic, MD, MSc, CCRP, Dermatologist
Associate Director, Medical Strategy and Scientific Affairs — Leo Pharma (USA)

• Kumaran Krishnan
European Medical Affairs Centre of Excellence — Sanofi (UK)

• Elizabeth Kupferer, PhD, WHNP-BC
Senior Medical Science Liaison III — Bayer HealthCare (USA)

• Merrell Lim, PharmD
Medical Advisor — AstraZeneca (Singapore)

• Luisa Luciani, PhD
Medical Science Liaison, Multiple Sclerosis — Genzyme (Australia)

• Tiffany MacKenzie, PhD
Manager, Scientific Affairs — DiaSorin (USA)

• Paul Meade, MPH, MS
President — Thought Leader Select (USA) Michael Pietrack
Vice President Medical Affairs Recruiting — TMAC Direct (USA)

• Michael Milane, MD, MBA
Director of Medical Affairs — Dusa Pharmaceuticals (USA)

• Richey Neuman, MD, MPH, FACP
Vice President, Head of Medical Affairs — Hyperion Therapeutics (USA)

• Ayse Ölmez, MD, MSc
Group Medical Manager — Bayer (Turkey)

• Michael Pietrack
Vice President Medical Affairs Recruiting — TMAC Direct (USA)

• Tom Peddicord, Pharm.D., FCCP
Account Group Director, Healthcare — Global Prairie (USA)

• Jennifer Williams, PhD, RN, MS, MBA
Director of TTM Education and Medical Science Liaison Services — Bard Medical (USA)
Contact Information
Thought Leader Select
Brian Castle